Selecky Christobel sold $1.4M of IBRX
Selecky Christobel sold 159,478 shares of ImmunityBio, Inc. (IBRX) at $9.02 ($1.44M total) on 2026-07-01 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The disclosed fact is the size and completion of the director’s sale (159,478 shares) and that holdings dropped to zero; however, the 10b5-1 designation reduces interpretive weight.
Market read
Traders may note the insider sale for sentiment, but there is no new fundamental catalyst in the text.
What to watch
The article doesn’t include any concurrent buys, changes in other insiders’ positions, or new company guidance—so the signal-to-noise is low.
Background
The article reports an SEC Form 4 insider transaction by a director of ImmunityBio, Inc. (IBRX).
Ticker impact
ImmunityBio director Selecky Christobel sold 159,478 shares in an open-market transaction worth about $1.44M, leaving 0 shares.
Low near-term impact; any reaction is likely muted unless paired with other disclosures.
The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and the article provides no new operational/regulatory/financial catalyst.
Market effects
Minimal; this is company-specific insider activity with no sector-wide signal provided.
None indicated.
None indicated.
Counterpoint
Because the sale was executed under a pre-arranged 10b5-1 plan, it may reflect scheduled liquidity rather than bearish expectations.
Key entities
- issuerImmunityBio, Inc.
US-listed company whose director filed the Form 4 insider sale disclosure.
- insiderSelecky Christobel
Director who sold 159,478 shares under a pre-arranged 10b5-1 plan.
